Skip to main content

Table 2 Baseline characteristics of patients with PBT and those without PBT in different HCC stage subset in the matched cohort (n = 576)

From: Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma

VariableBCLC 0-A (n = 317)BCLC B-C (n = 259)
PBT
n = 156)
Non-PBT
(n = 161)
P-valuePBT
(n = 132)
Non-PBT
(n = 127)
P-value
Demographic factors
 Age, yr52.7 ± 12.353.1 ± 12.40.78749.2 ± 12.651.4 ± 13.10.182
Sex, n (%)
 Male127 (81.4)126 (78.3)0.487118 (89.4)115 (90.6)0.758
 Female29 (18.6)35 (21.7) 14 (10.6)12 (9.4) 
HBsAg, n (%)
 Positive132 (84.6)138 (85.7)0.784112 (84.8)103 (81.1)0.424
 Negative24 (15.4)23 (14.3) 20 (15.2)24 (18.9) 
Cirrhosis, n (%)
 Yes144 (73.1)121 (75.2)0.674101 (76.5)93 (73.2)0.544
 No42 (26.9)40 (24.8) 31 (23.5)34 (26.8) 
 Hemoglobin, g/L132.0 ± 21.5133.4 ± 19.80.548136.3 ± 21.1133.4 ± 19.40.245
 Platelet count, ×109 /L201.8 ± 93.3180.6 ± 71.30.023197.8 ± 85.0207.9 ± 73.40.307
 Prothrombin time, s12.9 ± 1.612.9 ± 0.10.70513.0 ± 1.113.0 ± 1.10.894
 ALT, U/L, median (range)38 (6293)34 (71428)0.93144 (8, 237)38 (12,522)0.541
ALBI grade, n (%)
 Grade 182 (52.5)77 (47.8)0.48664 (48.4)53 (41.7)0.341
 Grade 272 (46.2)83 (51.6) 67 (50.8)74 (58.3) 
 Grade 32 (1.3)1 (0.6) 1 (0.8)0 
Inflammatory factors
 NLR, median (range)2.2 (0.52,13.03)2.1 (0.3, 24.9)0.9042.3 (0.9, 24.4)2.5 (1.1, 15.8)0.901
 PLR, median (range)117.8 (21.4, 405.4)107.8 (19.4, 414.0)0.379118.4 (19.8, 460.3)131.1 (20.6, 314.6)0.440
 APRI, median (range)0.5 (0.1, 5.3)0.5 (0.1, 21.1)0.6210.6 (0.1, 3.8)0.5 (0.1, 5.7)0.269
Tumor characteristics
 AFP, ug/L
   ≥ 40064 (41.0)60 (37.3)0.49361 (46.2)70 (55.1)0.153
   < 40092 (59.0)101 (68.9) 71 (53.8)57 (44.9) 
  Tumor size, cm8.4 ± 4.47.69 ± 3.860.1109.8 ± 3.510.1 ± 3.50.441
Tumor number, n (%)
 Solitary153 (98.1)156 (96.7)0.50238 (28.8)45 (35.4)0.524
 23 (1.9)5 (3.1) 48 (36.4)45 (35.4) 
 300 16 (12.1)4 (3.2) 
 400 30 (22.7)33 (26.0) 
Tumor capsule, n (%)
 Complete127 (81.4)135 (83.9)0.56886 (65.2)81 (63.8)0.818
 Incomplete29 (18.6)26 (16.1) 46 (34.8)46 (36.2) 
Differentiation, n (%)
 I+ II108 (69.2)111 (68.9)0.95688 (66.7)85 (66.9)0.964
 III, IV48 (30.8)50 (16.1) 44 (33.3)42 (33.1) 
MVI, n (%)
 Yes35 (22.4)33 (20.5)0.67462 (47.0)66 (52.0)0.196
 No121 (77.6)128 (79.5) 70 (53.0)61 (48.0) 
PVTT, n (%)
 Yes00 68 (51.5)72 (56.7)0.405
 No156 (100)161 (100) 64 (48.5)55 (43.3) 
HVTT
 Yes00 9 (6.8)5 (3.9)0.307
 No156 (100)161 (100) 123 (93.2)122 (96.1) 
Surgical factors
 Extent of resection, n (%)
  Major59 (37.8)58 (36.0)0.74191 (68.9)83 (65.4)0.541
  Minor97 (62.2)103 (64.0) 41 (31.1)44 (34.6) 
Type of resection, n (%)
 Anatomical55 (35.3)53 (32.9)0.66268 (51.5)69 (54.3)0.651
 nonanatomical101 (64.7)108 (67.1) 64 (48.5)58 (45.7) 
Resection margin, cm
  ≤ 151 (32.7)45 (28.0)0.35899 (75.0)100 (78.7)0.476
  > 1105 (67.3)116 (72.0) 33 (25.0)27 (21.3) 
Pringle maneuver, n (%)
 Yes56 (35.9)46 (28.6)0.163100 (75.7)98 (77.2)0.790
 No100 (64.1)115 (71.4) 32 (24.3)29 (22.7) 
Blood loss, ml, median (range)a1000 (50, 12,000)200 (50,3000)< 0.0011000 (15,7000)300 (50,2500)< 0.001
Clavien-Dindo gradea
 I3 (1.9)3 (1.9)0.9231 (0.8)4 (3.1)0.689
 II1 (0.6)3 (1.9) 1 (0.8)2 (1.6) 
 III12 (7.7)12 (7.5) 6 (4.5)7 (5.5) 
 IV2 (1.3)1 (0.6) 2 (1.5)1 (0.8) 
  1. aVariables are not included in the matching model
  2. Abbreviation: ABLI grade albumin to bilirubin grade, ALT anlanine transaminase, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, APRI alanine transaminase to platelet ratio index, PVTT portal vein tumor thrombus, HVTT hepatic vein tumor thrombus, MVI microscopic vascular invasion, AFP alpha fetoprotein, PLR platelet to lymphocyte ratio